CN101495513B - 促血管生成素-2特异性结合剂 - Google Patents

促血管生成素-2特异性结合剂 Download PDF

Info

Publication number
CN101495513B
CN101495513B CN200580043569.5A CN200580043569A CN101495513B CN 101495513 B CN101495513 B CN 101495513B CN 200580043569 A CN200580043569 A CN 200580043569A CN 101495513 B CN101495513 B CN 101495513B
Authority
CN
China
Prior art keywords
antibody
seq
ang
specific
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200580043569.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN101495513A (zh
Inventor
J·D·奥利纳
K·格雷汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN101495513A publication Critical patent/CN101495513A/zh
Application granted granted Critical
Publication of CN101495513B publication Critical patent/CN101495513B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200580043569.5A 2004-10-19 2005-10-19 促血管生成素-2特异性结合剂 Expired - Fee Related CN101495513B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US60/620,161 2004-10-19
US10/982,440 2004-11-04
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (2)

Publication Number Publication Date
CN101495513A CN101495513A (zh) 2009-07-29
CN101495513B true CN101495513B (zh) 2014-08-06

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580043569.5A Expired - Fee Related CN101495513B (zh) 2004-10-19 2005-10-19 促血管生成素-2特异性结合剂

Country Status (10)

Country Link
JP (2) JP2008520188A (es)
CN (1) CN101495513B (es)
BR (1) BRPI0518209A (es)
EA (1) EA011866B1 (es)
IL (1) IL182279A0 (es)
MA (1) MA29015B1 (es)
MX (1) MX2007004247A (es)
RU (2) RU2404992C2 (es)
SG (1) SG156668A1 (es)
ZA (1) ZA200704020B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520188A (ja) * 2004-10-19 2008-06-19 アムジエン・インコーポレーテツド アンジオポエチン−２特異的結合物質
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
BR112014007487A2 (pt) * 2011-09-30 2017-04-04 Dana Farber Cancer Inst Inc peptídeos terapêuticos
WO2013112438A1 (en) * 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
SG11201509278XA (en) * 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
IL302218B1 (en) 2014-08-28 2024-06-01 Eisai R&D Man Co Ltd Methods for the production of lanvotinib and its derivatives in a high degree of purity
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
AU2020227580A1 (en) * 2019-02-25 2021-09-30 Pharmabcine Inc. Anti-Ang2 antibody and use thereof
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487A (zh) * 2021-12-16 2023-06-20 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165115B1 (en) * 1999-03-26 2003-05-28 Regeneron Pharmaceuticals, Inc. Modulation of vascular permeability by mean of tie2 receptor activators
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
EP2332523B8 (en) * 2001-10-12 2022-04-20 Aquestive Therapeutics, Inc. Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
JP2008520188A (ja) * 2004-10-19 2008-06-19 アムジエン・インコーポレーテツド アンジオポエチン−２特異的結合物質

Also Published As

Publication number Publication date
SG156668A1 (en) 2009-11-26
ZA200704020B (en) 2008-06-25
MX2007004247A (es) 2007-06-12
JP2008520188A (ja) 2008-06-19
JP2011207882A (ja) 2011-10-20
BRPI0518209A (pt) 2008-11-04
RU2010132956A (ru) 2012-02-10
RU2007118670A (ru) 2008-12-27
EA200700876A1 (ru) 2007-10-26
RU2404992C2 (ru) 2010-11-27
CN101495513A (zh) 2009-07-29
MA29015B1 (fr) 2007-11-01
EA011866B1 (ru) 2009-06-30
IL182279A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
CN101495513B (zh) 促血管生成素-2特异性结合剂
US7658924B2 (en) Angiopoietin-2 specific binding agents
US7449555B2 (en) Antibodies of angiogenesis inhibiting domains CD148
TWI476206B (zh) 對肝細胞生長因子具專一性之結合劑
US7790674B2 (en) Methods of treatment using specific binding agents of human angiopoietin-2
US9701743B2 (en) Complement component C5 antibodies
CN106232624A (zh) 补体因子Bb抗体
US8119128B2 (en) Antibodies that bind urokinase-type plasminogen activator and epitopes therefor
CN107207585A (zh) 补体组分c5抗体
WO2007095583A2 (en) Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin
ZA200608757B (en) Antibodies of angiogenesis inhibiting domains of CD148

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1136836

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140806

Termination date: 20141019

EXPY Termination of patent right or utility model
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1136836

Country of ref document: HK